Detection of Clostridium difficile in 40 minutes*
Xpert® C. difficile/Epi – Identify. Differentiate. Prevent.
Numerous outbreaks caused by the epidemic strain of C. difficile (027/NAP1/BI strain) highlight the need for rapid and accurate differentiation of C. difficile 027/NAP1/BI strains in order to stay ahead of an outbreak.
- Higher risk of cross contamination with 027/NAP1/BI strain due to more efficient sporulation1,2,3
- 027/NAP1/BI strain has been identified as a cause of outbreaks around the world4,5,6,7,8
- Incremental costs due to C. difficile infection can be as high as $7,1799 per patient
1. Åkerlund T, et al. Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol. Apr 2008, 46 (4) 1530-1533.
2. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 Sep 24-30;366(9491):1079-84.
3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64.
4. Kallen AJ, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72.
5. Kuijper EJ, et al. Update of Clostridium difficile-associated Disease due to PCR Ribotype 027 in Europe. Eurosurveillance. Apr–Jun 2007. 12(3-6):163-166.
6. Muto CA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis. 2007 Nov 15;45(10):1266-73.
7. McDonald LC, et al. An Epidemic, Toxin Gene-variant Strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.
8. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442
9. Jarvis WR, et al. National Point Prevalence of Clostridium difficile in US Health Care Facility Inpatients, 2008. Am J Infect Control. 2009 May;37(4):263-70.
10. Xpert® C. difficile/Epi Package Insert. 300-9680, Rev J. Apr 2020.
Xpert C. difficile/Epi is the first commercially available test in the world to detect and differentiate the epidemic strain of C. difficile (027/NAP1/BI). With rapid and accurate identification of epidemic strain, Infection Control professional can stay ahead of potential outbreak situation.
- Innovative multiplex design enables detection of C. difficile Infection (CDI) and 027/NAP1/BI strain call-out in a single cartridge
- On-Demand testing of samples from suspected CDI patients provides On-Demand epidemiological surveillance data clinicians can act on
- Monitoring and reporting of the epidemic strain enables clinicians to improve infection control efforts
Cepheid's Xpert C. difficile/Epi test provides on-demand results you can trust and empowers your clinical team to better manage patients.
Xpert® C. difficile/Epi
Number of Tests: 10Catalog #: GXCDIFF/EPI-10
Xpert® C. difficile/Epi
Number of Tests: 120Catalog #: GXCDIFF/EPI-120
Catawba Valley Medical Center leverage the GeneXpert® for HAI Testing
Catawba Valley Medical Center, a non-profit, locally controlled community hospital in Hickory North Carolina highlights how they utilize the GeneXpert System throughout the hospital to improve patient care.
Cepheid's One-Hour PCR Technology
Cepheid’s one-hour PCR technology enabled VAMC Houston to quickly identify and isolate MRSA colonized and C. difficile positive patients resulting in lower HAI rates.
Ephraim McDowell Regional Medical Center
Ephraim McDowell Regional Medical Center improves adherence to optimized testing protocols for C. difficile resulting in lower C. difficile rates and decreased patient time in isolation.
White Paper: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance
CDC has declared the complex problem of antimicrobial resistance (AMR) a serious threat today, which will result in potential catastrophic consequences with continued inaction. To combat AMR, the CDC has identified 4 core actions, all of which can be addressed through rapid molecular diagnostics: